6-(4-methyl-piperazino)-[1,3,5]triazine-2,4-diyldiamine | 16274-55-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 6-(4-methyl-piperazino)-[1,3,5]triazine-2,4-diyldiamine
• 英文别名: 6-(4-Methyl-piperazino)-[1,3,5]triazin-2,4-diyldiamin；6-(4-Methylpiperazin-1-yl)-1,3,5-triazine-2,4-diamine
• CAS: 16274-55-8
• 化学式: C₈H₁₅N₇
• 分子量: 209.254
• InChiKey: HRQGDUJSSJGYLC-UHFFFAOYSA-N

物化性质

• 沸点：
  470.1±55.0 °C(Predicted)
• 密度：
  1.332±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  97.2
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  N-甲基哌嗪 、 2-氯-4,6-二氨基-1,3,5-三嗪 在 水 作用下， 生成 6-(4-methyl-piperazino)-[1,3,5]triazine-2,4-diyldiamine
  参考文献：
  名称：

  Foye; Chafetz, Journal of the American Pharmaceutical Association (1912), 1957, vol. 46, p. 366,369

  摘要：

  DOI：

文献信息

• Methods and compositions of novel triazine compounds
  申请人：Timmer T. Richard

  公开号：US20060258641A1

  公开（公告）日：2006-11-16

  The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

  本发明涉及包含治疗由炎症反应引起的病理生理状态的化合物的方法和组合物。特别地，本发明涉及抑制或阻断糖基化蛋白质诱导内皮细胞信号相关炎症反应的化合物。本发明涉及抑制平滑肌增殖的化合物。特别地，本发明涉及通过调节HSPG（如Perlecan）抑制平滑肌细胞增殖的化合物。本发明进一步涉及使用化合物治疗以平滑肌增殖为特征的血管闭塞性疾病，如再狭窄和动脉硬化。
• US7332490B2
  申请人：——

  公开号：US7332490B2

  公开（公告）日：2008-02-19
• [EN] NOVEL COMPOUNDS AS BTK INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS UTILISÉS COMME INHIBITEURS DE BTK
  申请人：SUN PHARMA ADVANCED RES CO LTD

  公开号：WO2017168454A2

  公开（公告）日：2017-10-05

  The present invention relates to novel compounds of Formula I as Bruton tyrosine kinase inhibitors, process of preparation thereof, and to the use of the compounds in the preparation 5 of pharmaceutical compositions for the therapeutic treatment of disorders involving mediation of Bruton tyrosine kinase in humans.
• Foye; Chafetz, Journal of the American Pharmaceutical Association (1912), 1957, vol. 46, p. 366,369
  作者：Foye、Chafetz

  DOI：——

  日期：——